Drugs / ChAdOX1-VZV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05991427 | Nov 2023 → Nov 2024 | herpes zoster | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOX1-VZV | “Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)” NCT05991427 ↗ |
| Known as | Recombinant Zoster Vaccine (Adenovirus Vector) | “Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)” NCT05991427 ↗ |
| Modality | Vaccine | “Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)” NCT05991427 ↗ |
| Route | Intramuscular | “Experimental vaccine group, low dose, Intramuscular injection(IM)” NCT05991427 ↗ |